Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

CLERICO, Marinella
First
;
DE MERCANTI, STEFANIA FEDERICA;ARTUSI, Carlo Alberto;DURELLI, Luca;
2017

Abstract

Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
23
6
874
876
Multiple sclerosis; alemtuzumab; cytomegalovirus; cytomegalovirus reactivation; herpes virus; multiple sclerosis treatment
Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
File in questo prodotto:
File Dimensione Formato  
MSJ688350.FinalProof.Corrected.2017.01.03.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 834.22 kB
Formato Adobe PDF
834.22 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1633293
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 35
social impact